Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
GlaucomaAngle-Closure
Interventions
DEVICE

XEN45

XEN45 unilaterally implanted in the study eye

Trial Locations (16)

2150

Marsden Eye Specialists Parramatta /ID# 232761, Paramatta

3133

Eye Surgery Associates P/L ATF Eye Surgery Associates Unit Trust /ID# 232765, Vermont South

11217

Taipei Veterans General Hospital /ID# 232948, Taipei City

97002

Buddhist Tzu Chi General Hospital /ID# 232664, Hualien City

119082

Nuh Medical Centre /ID# 232905, Singapore

308433

Tan Tock Seng Hospital /ID# 233014, Singapore

VIC3065

Melbourne Eye Specialists /ID# 232767, Fitzroy

J7H 0E8

Institut de loeil des Laurentides /ID# 232780, Boisbriand

H1V 1G5

Ophthalmology Clinic Bellevue /ID# 232782, Montreal

L5L 1W8

Prism Eye Institute /ID# 232917, Mississauga

03080

Seoul National University Hospital /ID# 233099, Seoul

GU2 7XX

Royal Surrey County Hospital /ID# 233028, Guildford

M13 9WL

Manchester University NHS Foundation Trust /ID# 232808, Manchester

RH19 3DZ

Queen Victoria Hospital /ID# 232812, East Grinstead

CO4 5JL

East Suffolk and North Essex NHS Foundation Trust /ID# 232804, Colchester

EH3 9HE

NHS Lothian /ID# 233052, Edinburgh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03362931 - Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma | Biotech Hunter | Biotech Hunter